Zimmer Biomet Holdings, Inc. (ZBH) Stock Price & Analysis

Zimmer Biomet Holdings, Inc. (ZBH) closed at USD 98.81 on Thursday, October 22, 2026, up 4.16% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 98.81; the Oct 22, 2026 session ranged USD 95.43–98.92 on volume of 2,223,554 shares. Market capitalization is —, with a 52-week range of USD 79.12–104.15 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:22 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ZBH.md

Key facts (ZBH)

• Last four reported quarters (through Jun 30, 2026): revenue $8.51B, net income $807M (9.5% margin), free cash flow $1.52B (SEC filings).
• 7 of 80 tracked superinvestors hold ZBH (13F, Q2 2026): 0 new, 1 added, 6 reduced, 0 unchanged.
• Total return with dividends: 1Y -3.2% vs S&P 500 +14.9%; 5Y -29.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-04, EPS estimate USD 1.88, revenue estimate $2.04B.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ZBH)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ZBH)

P/E at fiscal year-ends: Dec 2025 25.3x, Dec 2024 23.8x, Dec 2023 24.9x.

Superinvestors (SEC 13F-HR, Q2 2026) (ZBH)

7 of 80 tracked investors hold ZBH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (ZBH)

Rating changes, last 120 days:

Total return (dividends reinvested) (ZBH)

ZBH revenue by product line (quarter ended Jun 30, 2026)

ZBH revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

ZBH suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 20, 2026.

Companies that name ZBH in their SEC reports

ZBH analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 09:22 UTC)

Technical Analysis (ZBH)

Nexqual's technical model rates ZBH "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:22 UTC.

Earnings (ZBH)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:22 UTC.

Financials & Fundamentals (ZBH)

Source: Nexqual, October 23, 2026 at 09:22 UTC.

Ownership (ZBH)

Source: Nexqual, October 23, 2026 at 09:22 UTC.

Leadership (ZBH)

Zimmer Biomet Holdings, Inc. is led by Ivan Tornos, President, CEO & Chairman of the Board, per Nexqual as of October 23, 2026 at 09:22 UTC.

Major Backers & Investors (ZBH)

Notable institutional backers of Zimmer Biomet Holdings, Inc. include Dodge & Cox Inc., Harris Associates L.P., Capital International Investors, according to Nexqual as of October 23, 2026 at 09:22 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:22 UTC.

From Zimmer Biomet Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)

Key Strengths & Strategy (as disclosed to the SEC)

• We are subject to FDA Quality Management System regulations governing design and manufacturing practices, testing, manufacturing quality assurance, labeling and record keeping and reporting requirements for our products, which apply both to our own and to our third-party manufacturers' operations.
• The FDA conducts announced and unannounced periodic and on-going inspections of medical device manufacturers to determine compliance with its Quality System, and other applicable, regulations.
• Our quality management system is based upon the requirements of ISO 13485, the FDA Quality Management System regulations, the MDD, the EU MDR and other applicable regulations for the markets in which we sell.
• We protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to proprietary information.

Partnerships

• We collaborate with healthcare professionals around the globe to advance the pace of innovation.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to complex and expensive laws and governmental regulations relating to the development, design, product standards, packaging, advertising, promotion, post-market surveillance, manufacturing, labeling and marketing of our products, non-compliance with which could adversely affect our business, financial condition and results of operations.
• We are substantially dependent on patent and other proprietary rights, and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in the payment of significant monetary damages and/or royalty payments, negatively impact our ability to sell current or future products, or prohibit us from enforcing our patent and other proprietary rights against others.
• We are involved in legal proceedings that may result in adverse outcomes.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:22 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt